Login / Signup

Romosozumab for the treatment of postmenopausal women at high risk of fracture.

Piet GeusensNatasha Appelman-DijkstraWillem F LemsJoop van den Bergh
Published in: Expert opinion on biological therapy (2022)
Compared to antiresorptive agents, its unique mechanism of action results in a quicker and greater increase in bone mineral density, it repairs and restores trabecular and cortical bone microarchitecture, and reduces fracture risk more rapidly and more effectively than alendronate, with persisting effects for at least two years after transition to antiresorptive agents. This finding has introduced the concept that, in patients at very high risk of fractures, the optimal sequence of treatment is to start with an osteoanabolic agent, followed by a potent AR drug. Recent national and international guidelines recommend the use of romosozumab as an initial treatment in patients at very high fracture risk without a history of stroke or myocardial infarction.
Keyphrases
  • bone mineral density
  • postmenopausal women
  • body composition
  • heart failure
  • atrial fibrillation
  • emergency department
  • clinical practice